NZ598125A - Apaf-1 inhibitor compounds - Google Patents
Apaf-1 inhibitor compoundsInfo
- Publication number
- NZ598125A NZ598125A NZ598125A NZ59812510A NZ598125A NZ 598125 A NZ598125 A NZ 598125A NZ 598125 A NZ598125 A NZ 598125A NZ 59812510 A NZ59812510 A NZ 59812510A NZ 598125 A NZ598125 A NZ 598125A
- Authority
- NZ
- New Zealand
- Prior art keywords
- apaf
- inhibitor compounds
- dioxopiperazin
- dichlorophenethyl
- fluorobenzyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200901757 | 2009-07-30 | ||
| PCT/ES2010/000349 WO2011012746A2 (es) | 2009-07-30 | 2010-07-29 | Compuestos inhibidores de apaf-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598125A true NZ598125A (en) | 2014-05-30 |
Family
ID=43529761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598125A NZ598125A (en) | 2009-07-30 | 2010-07-29 | Apaf-1 inhibitor compounds |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9040701B2 (enExample) |
| EP (1) | EP2460798B1 (enExample) |
| JP (1) | JP5694320B2 (enExample) |
| KR (1) | KR101786761B1 (enExample) |
| CN (1) | CN102574818B (enExample) |
| AU (1) | AU2010277505B2 (enExample) |
| BR (1) | BR112012002134B8 (enExample) |
| CA (1) | CA2769408C (enExample) |
| EA (1) | EA021838B1 (enExample) |
| ES (1) | ES2727711T3 (enExample) |
| IN (1) | IN2012DN01378A (enExample) |
| MX (1) | MX2012001339A (enExample) |
| NZ (1) | NZ598125A (enExample) |
| TR (1) | TR201907804T4 (enExample) |
| WO (1) | WO2011012746A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006138380A2 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| EP3269395A1 (en) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| EP3318248B1 (en) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| US9193827B2 (en) | 2010-08-26 | 2015-11-24 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
| EP2691443B1 (en) | 2011-03-28 | 2021-02-17 | Massachusetts Institute of Technology | Conjugated lipomers and uses thereof |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| PE20181541A1 (es) * | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| ES2443538B1 (es) * | 2012-07-19 | 2014-11-26 | Consejo Superior De Investigaciones Cientificas (Csic) | Compuestos beta-lactámicos inhibidores de APAF1 |
| WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| JP6586075B2 (ja) | 2013-03-14 | 2019-10-02 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの精製方法 |
| RS57739B1 (sr) | 2013-03-14 | 2018-12-31 | Translate Bio Inc | Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima |
| WO2014179562A1 (en) | 2013-05-01 | 2014-11-06 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
| JP6506749B2 (ja) | 2013-10-22 | 2019-04-24 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | フェニルケトン尿症のためのｍＲＮＡ療法 |
| CN106413811A (zh) | 2013-10-22 | 2017-02-15 | 夏尔人类遗传性治疗公司 | 精氨基琥珀酸合成酶缺乏症的mrna疗法 |
| ES3032935T3 (en) | 2013-10-22 | 2025-07-29 | Translate Bio Inc | Lipid formulations for delivery of messenger rna |
| US9850269B2 (en) | 2014-04-25 | 2017-12-26 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| JP6557722B2 (ja) | 2014-05-30 | 2019-08-07 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 核酸の送達のための生分解性脂質 |
| KR102559979B1 (ko) | 2014-06-24 | 2023-07-25 | 샤이어 휴먼 지네틱 테라피즈 인크. | 핵산의 전달용 입체화학적으로 풍부한 조성물 |
| US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| WO2016205691A1 (en) | 2015-06-19 | 2016-12-22 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
| AU2019256527B2 (en) | 2018-04-19 | 2025-01-23 | Spiral Therapeutics, Inc. | Inner ear drug delivery devices and methods of use |
| KR102950141B1 (ko) | 2018-08-24 | 2026-04-07 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 정제 방법 |
| WO2020106946A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR |
| US10561736B1 (en) | 2019-01-09 | 2020-02-18 | Spiral Therapeutics, Inc. | Apoptosis inhibitor formulations for prevention of hearing loss |
| WO2020176419A1 (en) | 2019-02-25 | 2020-09-03 | Spiral Therapeutics, Inc. | Intratympanic injector devices and needles for delivery of drugs and methods of use |
| EP4031662A1 (en) | 2019-09-20 | 2022-07-27 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| EP4093355B1 (en) | 2020-01-24 | 2025-09-24 | Spiral Therapeutics Inc. | Systems for treating hearing loss |
| EP4137131A1 (en) * | 2021-08-17 | 2023-02-22 | Centre National de la Recherche Scientifique (CNRS) | Novel serotonin analogues and their uses for treating iron-associated disorders |
| CN115124449B (zh) * | 2022-05-24 | 2024-02-02 | 上海英诺富成生物科技有限公司 | 一种吲哚化合物及制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560503A (en) * | 1968-09-18 | 1971-02-02 | Council Scient Ind Res | Di-lower alkyl-substituted octahydropyrazinopyrimidinones |
| GB1284582A (en) | 1969-11-10 | 1972-08-09 | Council Scient Ind Res | Substituted piperazinopyrimidinones |
| JPH04234375A (ja) | 1990-12-27 | 1992-08-24 | Ajinomoto Co Inc | 新規２，５−ジオキソピペラジン化合物及びその製造法 |
| WO1992019595A1 (en) * | 1991-05-07 | 1992-11-12 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH05117246A (ja) | 1991-10-23 | 1993-05-14 | Ajinomoto Co Inc | 新規２，５−ジオキソピペラジン化合物とその製造法及びα−Ｌ−アスパルチル−Ｌ−フエニルアラニンメチルエステル誘導体の製造法 |
| AU2871195A (en) * | 1994-06-23 | 1996-01-19 | Affymax Technologies N.V. | Methods for the synthesis of diketopiperazines |
| ATE277913T1 (de) * | 2001-01-19 | 2004-10-15 | Pharmacopeia Inc | Bisarylderivate mit fsh rezeptor modulierender aktivität |
| WO2004030522A2 (en) | 2002-10-02 | 2004-04-15 | Dmi Biosciences, Inc. | Diagnosis and monitoring of diseases |
| EP1698703A4 (en) | 2003-11-28 | 2011-08-17 | Kyowa Hakko Bio Co Ltd | PROCESS FOR DIPEPTIDE PRODUCTION |
| ES2296484B1 (es) * | 2005-11-23 | 2009-04-01 | Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) | Composicion farmaceutica para inhibir la apoptosis. |
| ES2293834B1 (es) * | 2006-07-20 | 2009-02-16 | Consejo Superior Investig. Cientificas | Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas. |
-
2010
- 2010-07-29 US US13/387,240 patent/US9040701B2/en active Active
- 2010-07-29 MX MX2012001339A patent/MX2012001339A/es active IP Right Grant
- 2010-07-29 EA EA201270215A patent/EA021838B1/ru not_active IP Right Cessation
- 2010-07-29 IN IN1378DEN2012 patent/IN2012DN01378A/en unknown
- 2010-07-29 EP EP10803937.1A patent/EP2460798B1/en active Active
- 2010-07-29 KR KR1020127005131A patent/KR101786761B1/ko not_active Expired - Fee Related
- 2010-07-29 TR TR2019/07804T patent/TR201907804T4/tr unknown
- 2010-07-29 JP JP2012522195A patent/JP5694320B2/ja not_active Expired - Fee Related
- 2010-07-29 BR BR112012002134A patent/BR112012002134B8/pt not_active IP Right Cessation
- 2010-07-29 ES ES10803937T patent/ES2727711T3/es active Active
- 2010-07-29 AU AU2010277505A patent/AU2010277505B2/en not_active Ceased
- 2010-07-29 CN CN201080043254.1A patent/CN102574818B/zh not_active Expired - Fee Related
- 2010-07-29 CA CA2769408A patent/CA2769408C/en active Active
- 2010-07-29 WO PCT/ES2010/000349 patent/WO2011012746A2/es not_active Ceased
- 2010-07-29 NZ NZ598125A patent/NZ598125A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010277505B2 (en) | 2016-01-14 |
| CA2769408C (en) | 2017-09-05 |
| IN2012DN01378A (enExample) | 2015-06-05 |
| EA021838B1 (ru) | 2015-09-30 |
| KR101786761B1 (ko) | 2017-10-18 |
| BR112012002134B1 (pt) | 2021-03-02 |
| CA2769408A1 (en) | 2011-02-03 |
| AU2010277505A1 (en) | 2012-03-08 |
| JP2013500314A (ja) | 2013-01-07 |
| EP2460798A2 (en) | 2012-06-06 |
| JP5694320B2 (ja) | 2015-04-01 |
| BR112012002134B8 (pt) | 2021-05-25 |
| MX2012001339A (es) | 2012-03-07 |
| TR201907804T4 (tr) | 2019-06-21 |
| EP2460798A4 (en) | 2013-02-27 |
| WO2011012746A2 (es) | 2011-02-03 |
| CN102574818A (zh) | 2012-07-11 |
| BR112012002134A2 (pt) | 2016-05-31 |
| US9040701B2 (en) | 2015-05-26 |
| EA201270215A1 (ru) | 2012-11-30 |
| EP2460798B1 (en) | 2019-02-27 |
| US20120122868A1 (en) | 2012-05-17 |
| ES2727711T3 (es) | 2019-10-18 |
| KR20120052354A (ko) | 2012-05-23 |
| CN102574818B (zh) | 2015-02-25 |
| WO2011012746A3 (es) | 2011-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ598125A (en) | Apaf-1 inhibitor compounds | |
| NZ599513A (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| NZ595073A (en) | Proline derivatives as cathepsin inhibitors | |
| MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
| TN2009000286A1 (en) | Amide substituted indazoles as poly (adp-ribose)polymerase (parp) inhibitors | |
| TW201000488A (en) | Heterocyclic derivatives | |
| EA200802329A1 (ru) | Производные триазола ii | |
| MX2011011733A (es) | Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. | |
| EA200970946A1 (ru) | Комбинированная терапия антикоагулирующего средства с соединением, которое действует как ингибитор фактора ха | |
| EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
| MX2013001204A (es) | Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares. | |
| UA107784C2 (en) | Inhibitor of melanin production | |
| TW200616953A (en) | Indole, indazole or indoline derivatives | |
| MX2012007582A (es) | Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida. | |
| EA201100872A1 (ru) | Производные хиназолинамида | |
| EA200900913A1 (ru) | Производное триазола в качестве ингибитора hsp90 | |
| TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
| HUE044513T2 (hu) | Amidszubsztituált indazolok mint poli(ADP-ribóz)polimeráz (PARP) inhibitorok | |
| WO2009082526A3 (en) | Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation | |
| ATE492534T1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
| TN2012000242A1 (en) | Heterocyclic sulfonamide derivatives | |
| MX2009013003A (es) | Derivados de piperidina-amida. | |
| PT2480232E (pt) | [4-(5-aminometil-fenil)-piperidin-1-il]-1h-indol-3-il]- metanonas dissubstituídas | |
| MX2012001107A (es) | Derivado de amida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 JUL 2017 BY COLLISON + CO Effective date: 20141120 |
|
| ASS | Change of ownership |
Owner name: LOOP THERAPEUTICS INC., US Effective date: 20160505 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JUL 2018 BY COMPUTER PACKAGES INC Effective date: 20170701 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JUL 2019 BY COMPUTER PACKAGES INC Effective date: 20180703 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JUL 2020 BY COMPUTER PACKAGES INC Effective date: 20190702 |
|
| ASS | Change of ownership |
Owner name: SPIRAL THERAPEUTICS INC., US Effective date: 20190904 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JUL 2021 BY COMPUTER PACKAGES INC Effective date: 20200701 |
|
| LAPS | Patent lapsed |